echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Good News|Boji Biomedical Bifunctional Fusion Protein Receives FDA Approval to Enter Clinical Trials

    Good News|Boji Biomedical Bifunctional Fusion Protein Receives FDA Approval to Enter Clinical Trials

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Boji Biomedical Technology (Hangzhou) Co.
    , Ltd.
    recently announced that the US FDA has completed the review of the PD-L1/TGFβ bifunctional fusion protein (product code BJ-005) IND independently developed by the company and has a global patent.
    The project can carry out clinical trials in the United States
    .


    This is after Boji Biomedicine obtained the IND approval of the US FDA for its first tumor-targeting IL-15 fusion protein (BJ-001) in 2019, another independently developed product obtained the US FDA's clinical trial approval


    Dr.
    Zhang Haizhou

    Regarding the approval of the US FDA for BJ-005, Dr.
    Haizhou Zhang, co-founder and CEO of Boji Biomedicine, said: "Our second self-developed product was approved for clinical trials in the United States, which once again proved Boji Biomedical The continuous innovation ability and efficient execution power of
    the company.


    This greatly enhances the company’s confidence in fulfilling the established goal of pushing a completely independent innovation product into clinical research every 1-2 years


    Although it has only been in operation for more than 3 years, but adhering to the concept of only making global independent innovative drugs, Boji Biopharmaceuticals has begun to conduct research on tumors and infectious diseases using its biological drug research and development platform protected by trade secrets and its self-developed dual antibody platform.
    Layout
    .


    The BJ-005, which was approved to enter the clinic this time, is one of many innovative products in its R&D pipeline


    About Boji Biomedicine

    Boji Biomedicine is a biotechnology company in the clinical stage dedicated to the research and development of innovative drugs.
    It was founded by returned experts with many years of experience in innovative drug research and development at home and abroad, including review experts for major scientific and technological projects of the country’s “Major New Drug Development” , Possesses an antibody discovery platform protected by trade secrets and advanced technologies at home and abroad.
    Currently, it mainly develops biological drugs for tumors and infectious diseases
    .


    The company's main scientific research and management team has many years of experience in the development and management of macromolecular drugs in national key scientific research institutions and domestic and foreign pharmaceutical companies, especially European and American multinational companies


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.